1599529-10-8

Basic information

• Product Name: (1-methyl-1H-imidazol-5-yl)(4-nitrophenyl)methanone
• Synonyms: (1-methyl-1H-imidazol-5-yl)(4-nitrophenyl)methanone
• CAS NO: 1599529-10-8
• Molecular Weight: 231.211
• Mol File: 1599529-10-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (1-methyl-1H-imidazol-5-yl)(4-nitrophenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (1-methyl-1H-imidazol-5-yl)(4-nitrophenyl)methanone(1599529-10-8)
• EPA Substance Registry System: (1-methyl-1H-imidazol-5-yl)(4-nitrophenyl)methanone(1599529-10-8)

Safety Data

• Hazardous Substances Data: 1599529-10-8(Hazardous Substances Data)

Usage

Description

(1-methyl-1H-imidazol-5-yl)(4-nitrophenyl)methanone is a small molecule chemical compound consisting of a methyl-imidazole group, a nitrophenyl group, and a methanone group. With a molecular formula of C12H10N4O3, this compound is characterized by its potential pharmaceutical properties due to the presence of biologically active imidazole and nitrophenyl moieties.

Uses

Used in Pharmaceutical Industry:
(1-methyl-1H-imidazol-5-yl)(4-nitrophenyl)methanone is used as a pharmaceutical compound for its potential biological activity. The presence of imidazole and nitrophenyl groups suggests that it may have applications in the development of drugs targeting various diseases and conditions. Further research is required to explore its specific therapeutic uses and efficacy.
Used in Chemical Research:
In the field of chemical research, (1-methyl-1H-imidazol-5-yl)(4-nitrophenyl)methanone serves as a subject for studying the properties and reactions of small molecules containing imidazole and nitrophenyl groups. This can contribute to the understanding of their reactivity, stability, and potential applications in various chemical processes and syntheses.

Upstream product

• 1003-21-0 5-bromo-N-methylimidazole 
• 52898-51-8 N-methoxy-N-methyl-4-nitrobenzamide 
• 925-90-6 ethylmagnesium bromide 
• 62-23-7 4-nitro-benzoic acid 

Downstream Products

• 1599529-11-9 (4-aminophenyl)(1-methyl-1H-imidazol-5-yl)methanone 
• 1599530-87-6 (4-chloro-2-methoxy-3-(4-(methylsulfonyl)benzyl)quinolin-6-yl)(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methanol 
• 1599529-31-3 (4-chloro-2-methoxy-3-(4-(methylsulfonyl)benzyl)quinolin-6-yl)(1-methyl-1H-imidazol-5-yl)methanone 
• 1599529-30-2 (2,4-dichloro-3-(4-(methylsulfonyl)benzyl)quinolin-6-yl)(1-methyl-1H-imidazol-5-yl)methanone 
• 1599529-12-0 (3-(4-(1H-pyrazol-1-yl)benzyl)-2,4-dichloroquinolin-6-yl)(1-methyl-1H-imidazol-5-yl)methanone 

Relevant articles and documents

ALKYL LINKED QUINOLINYL MODULATORS OF RORγt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

ALKYL LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.